Loading...

PainChek

ASX:PCK
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PCK
ASX
A$177M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

PainChek Ltd. provides pain assessment solutions primarily in Australia and Europe. The last earnings update was 142 days ago. More info.


Add to Portfolio Compare Print
  • PainChek has significant price volatility in the past 3 months.
PCK Share Price and Events
7 Day Returns
0%
ASX:PCK
1.7%
AU Healthcare Services
-0.9%
AU Market
1 Year Returns
313%
ASX:PCK
137.6%
AU Healthcare Services
4.2%
AU Market
PCK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PainChek (PCK) 0% 0% 493.8% 313% - -
AU Healthcare Services 1.7% 17.8% 63.2% 137.6% 90.7% 877.1%
AU Market -0.9% 1.4% 6% 4.2% 19% 11%
1 Year Return vs Industry and Market
  • PCK outperformed the Healthcare Services industry which returned 137.6% over the past year.
  • PCK outperformed the Market in Australia which returned 4.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

PCK Value

 Is PainChek undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for PainChek. This is due to cash flow or dividend data being unavailable. The share price is A$0.19.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PainChek's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PainChek's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:PCK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.00
ASX:PCK Share Price ** ASX (2019-07-19) in AUD A$0.19
Global Healthcare Services Industry PE Ratio Median Figure of 38 Publicly-Listed Healthcare Services Companies 37.87x
Australia Market PE Ratio Median Figure of 546 Publicly-Listed Companies 16.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PainChek.

ASX:PCK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:PCK Share Price ÷ EPS (both in AUD)

= 0.19 ÷ 0.00

-60.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PainChek is loss making, we can't compare its value to the Global Healthcare Services industry average.
  • PainChek is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does PainChek's expected growth come at a high price?
Raw Data
ASX:PCK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -60.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Healthcare Services Industry PEG Ratio Median Figure of 25 Publicly-Listed Healthcare Services Companies 2.28x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PainChek, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PainChek's assets?
Raw Data
ASX:PCK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.00
ASX:PCK Share Price * ASX (2019-07-19) in AUD A$0.19
Australia Healthcare Services Industry PB Ratio Median Figure of 15 Publicly-Listed Healthcare Services Companies 5.13x
Australia Market PB Ratio Median Figure of 1,693 Publicly-Listed Companies 1.7x
ASX:PCK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:PCK Share Price ÷ Book Value per Share (both in AUD)

= 0.19 ÷ 0.00

76.86x

* Primary Listing of PainChek.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PainChek is overvalued based on assets compared to the AU Healthcare Services industry average.
X
Value checks
We assess PainChek's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. PainChek has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PCK Future Performance

 How is PainChek expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PainChek has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.1%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PainChek expected to grow at an attractive rate?
  • Unable to compare PainChek's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare PainChek's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare PainChek's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:PCK Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 36.1%
Australia Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 31.1%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7.4%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:PCK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:PCK Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -3 -3
2018-09-30 0 -3 -4
2018-06-30 0 -3 -5
2018-03-31 0 -3 -5
2017-12-31 0 -3 -5
2017-09-30 0 -2 -7
2017-06-30 0 -2 -8
2016-06-30 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if PainChek is high growth as no earnings estimate data is available.
  • Unable to determine if PainChek is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:PCK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from PainChek Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PCK Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.02
2016-06-30 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PainChek will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine PainChek's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. PainChek's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. PainChek's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess PainChek's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PainChek has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PCK Past Performance

  How has PainChek performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PainChek's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PainChek does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare PainChek's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare PainChek's 1-year growth to the Global Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
PainChek's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PainChek Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PCK Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.14 -2.61 2.08 1.83
2018-09-30 0.10 -3.71 1.97 1.76
2018-06-30 0.05 -4.81 1.86 1.70
2018-03-31 0.05 -4.86 1.87 1.57
2017-12-31 0.05 -4.91 1.88 1.43
2017-09-30 0.04 -6.69 2.53 1.13
2017-06-30 0.03 -8.47 3.18 0.82
2016-06-30 0.00 -0.16 0.08 0.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if PainChek has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if PainChek has efficiently used its assets last year compared to the Global Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if PainChek improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess PainChek's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PainChek has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PCK Health

 How is PainChek's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PainChek's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PainChek is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PainChek has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of PainChek's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • PainChek has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PainChek Company Filings, last reported 6 months ago.

ASX:PCK Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2.07 0.00 2.33
2018-09-30 2.07 0.00 2.33
2018-06-30 3.22 0.00 3.61
2018-03-31 3.22 0.00 3.61
2017-12-31 4.41 0.00 4.69
2017-09-30 4.41 0.00 4.69
2017-06-30 2.48 0.00 2.63
2016-06-30 0.07 0.00 0.08
  • PainChek has no debt.
  • PainChek has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • PainChek has less than a year of cash runway based on current free cash flow.
  • PainChek has less than a year of cash runway if free cash flow continues to grow at historical rates of 49% each year.
X
Financial health checks
We assess PainChek's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PainChek has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PCK Dividends

 What is PainChek's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from PainChek dividends.
If you bought A$2,000 of PainChek shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate PainChek's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate PainChek's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:PCK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 16 Stocks 1.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 415 Stocks 4.1%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.6%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as PainChek has not reported any payouts.
  • Unable to verify if PainChek's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of PainChek's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as PainChek has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess PainChek's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PainChek afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PainChek has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PCK Management

 What is the CEO of PainChek's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Philip Daffas
COMPENSATION A$401,867
TENURE AS CEO 2.8 years
CEO Bio

Mr. Philip Daffas, BSc, Dip EENG, MBA, GAICD, has been Managing Director at PainChek Ltd. since September 30, 2016 and has been its Director since September 30, 2016. Mr. Daffas served as Vice President of Global Marketing and Sales at Pelikan Technologies, Inc. He served as Vice President of Marketing at Cochlear Limited.

CEO Compensation
  • Philip's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Philip's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the PainChek management team in years:

2.8
Average Tenure
  • The tenure for the PainChek management team is about average.
Management Team

Philip Daffas

TITLE
MD & Director
COMPENSATION
A$402K
TENURE
2.8 yrs

Ian Hobson

TITLE
CFO & Company Secretary
COMPENSATION
A$122K
AGE
54
TENURE
2.8 yrs

Scott Robertson

TITLE
Chief Technology Officer
TENURE
2.3 yrs

Jeff Hughes

TITLE
Chief Scientific Officer

David Allsopp

TITLE
Head of Business Development ANZ
Board of Directors Tenure

Average tenure of the PainChek board of directors in years:

2.8
Average Tenure
  • The average tenure for the PainChek board of directors is less than 3 years, this suggests a new board.
Board of Directors

John Murray

TITLE
Non-Executive Chairman
COMPENSATION
A$146K
TENURE
2.8 yrs

Philip Daffas

TITLE
MD & Director
COMPENSATION
A$402K
TENURE
2.8 yrs

Adam Davey

TITLE
Non-Executive Director
COMPENSATION
A$73K
AGE
74
TENURE
4.8 yrs

Ross Harricks

TITLE
Non-Executive Director
COMPENSATION
A$73K
AGE
75
TENURE
2.8 yrs

Jennifer Abbey

TITLE
Member of Clinical Advisory Board
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess PainChek's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PainChek has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PCK News

Simply Wall St News

Imagine Owning PainChek (ASX:PCK) While The Price Tanked 58%

So it seems shareholders are too busy dreaming about the progress to come than dwelling on the current (lack of) revenue. … It seems likely some shareholders believe that PainChek will significantly advance the business plan before too long. … There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders.

Simply Wall St -

PainChek Ltd. (ASX:PCK): Time For A Financial Health Check

(ASX:PCK), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is PCK growing fast enough to value financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

What Kind Of Shareholders Own PainChek Ltd. (ASX:PCK)?

The big shareholder groups in PainChek Ltd. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of AU$34m, PainChek is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Is PainChek Ltd's (ASX:PCK) Balance Sheet Strong Enough To Weather A Storm?

The direct benefit for PainChek Ltd (ASX:PCK), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is PCK right in choosing financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

Before You Invest In PainChek Ltd (ASX:PCK), Consider This

Looking at PainChek’s latest financial data, I will gauge when the company may run out of cash and need to raise more money. … The measure of how fast PainChek goes through its cash reserves over time is called the cash burn rate. … My cash burn analysis suggests that PainChek has a cash runway of 1.4 years, given its current level of cash holdings.

Simply Wall St -

Why PainChek Ltd's (ASX:PCK) Ownership Structure Is Important

View our latest analysis for PainChek ASX:PCK Ownership_summary Apr 6th 18 Institutional Ownership Institutional investors are one of the largest group of market participants and their buy-sell decisions on a company's stock can significantly impact prices, more so, when there are relatively small amounts of shares available on the market to trade. … Insider Ownership Another important group of shareholders are company insiders. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market.

Simply Wall St -

Does PainChek Ltd's (ASX:PCK) Past Performance Indicate A Weaker Future?

For the purpose of this commentary, I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … ASX:PCK Income Statement Mar 9th 18 We can further assess PainChek's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years PainChek's top-line has grown by 98.00% on average, signalling that the company is in a high-growth period with expenses racing ahead revenues, leading to annual losses.

Simply Wall St -

What You Must Know About PainChek Ltd's (ASX:PCK) Financial Health

Zero-debt allows substantial financial flexibility, especially for small-cap companies like PainChek Ltd (ASX:PCK), as the company does not have to adhere to strict debt covenants. … Check out our latest analysis for PainChek Is financial flexibility worth the lower cost of capital? … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

PCK Company Info

Description

PainChek Ltd. provides pain assessment solutions primarily in Australia and Europe. The company offers PainChek, a smartphones pain assessment and monitoring device that automatically detects pain through facial recognition technology. It serves pre-verbal children and patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Ltd. in January 2018. PainChek Ltd. is based in Sydney, Australia.

Details
Name: PainChek Ltd.
PCK
Exchange: ASX
Founded:
A$176,798,451
906,658,727
Website: http://www.painchek.com
Address: PainChek Ltd.
35 Lime Street,
Suite 401,
Sydney,
New South Wales, 2000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX PCK Ordinary Shares Australian Securities Exchange AU AUD 22. Jan 2018
Number of employees
Current staff
Staff numbers
0
PainChek employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 10:40
End of day share price update: 2019/07/19 00:00
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.